Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Clinical trial NCT03541902 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03541902
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Neoplasms of Urinary Tract Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Papillary Renal Cell Carcinoma Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions Sarcomatoid Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v8 Unclassified Renal Cell Carcinoma

Start date: 2018-05-15
Primary completion: 2027-07-31
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.